Sürdürülebilir Kalkınma Amaçları
Yayınlar
- MakaleAçık Erişim2026Scopus SJRQ2Reliability and validity of the Turkish version of the pain attention and awareness questionnaire for nonspecific musculoskeletal pain
Sürmeli, Mahmut; Özdemir, Özlem Çinar; Topcuoğlu, Ceyhun
Background: Reliable and valid assessments of pain vigilance and awareness are crucial for understanding and treating pain within cognitive-behavioral frameworks, such as the fear-Avoidance Model. While the Pain Vigilance and Awareness Questionnaire (PVAQ) is a widely used tool for this purpose, no culturally adapted and validated version exists for the Turkish-speaking population, creating an instrumental and clinical gap. Objective: This study aimed to translate, culturally adapt, and comprehensively evaluate the psychometric properties of the Turkish version of the PVAQ in a sample of patients with nonspecific musculoskeletal pain. Methods: An instrumental, cross-sectional study was conducted. The PVAQ was translated and adapted into Turkish according to established guidelines. A sample of 131 patients with low back, neck, or shoulder pain completed the PVAQ-T, the Pain Catastrophizing Scale (PCS), the Tampa Scale for Kinesiophobia (TSK), the Hospital Anxiety and Depression Scale (HADS), and a visual analog scale (VAS) for pain intensity. Reliability was assessed via internal consistency (Cronbach’s alpha) and test-retest reliability (intraclass correlation coefficient - ICC). Construct validity was examined via exploratory factor analysis (EFA) and confirmatory factor analysis (CFA). Criterion validity was evaluated through Pearson correlations with the PCS, TSK, and HADS. Results: The PVAQ-T demonstrated acceptable internal consistency (Cronbach’s α = 0.83) and good test-retest reliability (ICC = 0.918). EFA supported a two-factor structure (vigilance and awareness), explaining 62.3% of the variance. CFA indicated that the original 16-item model had a suboptimal fit (CFI = 0.807; GFI = 0.732; SRMR = 0.060; RMSEA = 0.138, and χ²/df = 3.46). Following the removal of items 4 and 12 based on exploratory and item-level findings, some fit indices showed modest improvement (CFI = 0.836; GFI = 0.768; SRMR = 0.006), whereas others remained unchanged or worsened (RMSEA = 0.144; χ²/df = 3.69). The PVAQ-T total score showed moderately to strongly, statistically significant (p < 0.001) correlations with the PCS (r = 0.681), TSK (r = 0.694), HADS-Anxiety (r = 0.491), and HADS-Depression (r = 0.416) scores, supporting its criterion validity. Conclusion: Within a Turkish sample of individuals with nonspecific musculoskeletal pain, the 14-item Turkish version of the PVAQ demonstrates adequate reliability and validity for assessing pain-related attention and awareness. While the two-factor structure was supported at the exploratory level, confirmatory findings suggest that results should be interpreted with caution. The PVAQ-TR may be a useful instrument for research and clinical assessment of pain-related attentional processes, highlighting the importance of cultural adaptation and empirical evaluation of psychometric instruments.
- MakaleYayıncıda açık erişim2023Scopus SJRQ2The Symptom Experience and Functioning of Non-Hospitalized COVID-19 Patients Within the First 20 days
Tütün Yümin, Eylem; Sürmeli, Mahmut; Topcuoğlu, Ceyhun; Başol Göksülük, Merve; Yümin, Murat
The adverse physical, psychological, and mental health consequences associated with COVID-19 illness are well-documented. However, how specific symptoms change over time and how COVID-19 affects one’s day-to-day activities of daily living (ADL), Quality of Life (QoL), sleep quality, and fatigue severity are not well described. This longitudinal and descriptive study examined the changes in COVID-19 symptoms, ADL, QoL, sleep quality, and fatigue severity within the first 20 days. A convenience sample (n = 41) of non-hospitalized SARS-CoV-2 positive patients were recruited and followed for 20 days. Participants completed self-report measures: COVID-19 symptoms, ADL, QoL, sleep quality, and fatigue severity at days: 1, 10, and 20 following a diagnosis. Findings revealed that symptoms decreased over 20 days (p <.001). In parallel with the decrease in symptoms, QoL and ADL improved over 20 days (p <.05). However, sleep quality and fatigue severity did not improve within 20 days (p >.05). Our findings contribute to the growing evidence that COVID-19 symptoms can linger, especially fatigue and sleep quality, that affect overall day-to-day functioning for at least 20 days after diagnosis. To mitigate the effect of COVID-19 on QOL and ADL, findings underscore the need for clinicians to work collaboratively with patients to develop a symptom management plan for a variety of symptoms including fatigue and sleep quality. Beginning to repurpose existing self-management strategies for the longer term COVID-19 symptoms could be beneficial and help to optimize patient outcomes. Future work should examine these variables over a longer timeframe and among different samples of non-hospitalized patients.
AtıfScopus1WoS1
İncele